Product is First Non-Factor and Once-Weekly Treatment for Hemophilia B SILVER SPRING, Md., Oct. 11, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in…